A novel opioid receptor antagonist for treating abuse and overdose

一种用于治疗滥用和过量的新型阿片受体拮抗剂

基本信息

项目摘要

ABSTRACT Deaths from opioid overdose continue to rise; from 2015-2016, there was a 28% increase in the number of fatal overdoses. Fentanyl derivatives are inexpensive, easy to synthesize, potent, and marketed to unsuspecting abusers as heroin or other drugs. Moreover, the effects of fentanyl derivatives are reportedly more difficult to reverse with naloxone, compared with reversal of heroin. Pharmacotherapies for opioid abuse include the µ opioid receptor agonists methadone and buprenorphine that are effective in many patients, although both drugs have limitations, including diversion and abuse, and they can have serious unwanted effects, including respiratory depression and death. The opioid receptor antagonists naltrexone and naloxone avoid the abuse liability and adverse effects of methadone and buprenorphine; however, short durations of action and surmountability limit their effectiveness. A medication with a longer duration of action that prevents and reverses the effects of opioids in a manner that is not surmounted by increasing doses of agonist could improve significantly treatment of abuse and save lives by providing insurmountable extended protection after rescue from overdose. Our pilot studies in monkeys show that the pseudoirreversible, µ opioid receptor selective antagonist methocinnamox (MCAM) decreases heroin but not cocaine self-administration, decreases choice for remifentanil in a food/drug choice procedure, and reverses as well as protects against respiratory depression by heroin, with a single injection being effective for a week or longer. Proposed studies build on these compelling data and examine the long-term antagonist properties and the pharmacokinetics of MCAM in combination with commonly abuse opioids, including ultra-potent fentanyl analogs. MCAM is hypothesized to be better than naloxone and naltrexone in reversing and preventing the effects of opioid receptor agonists and, in particular, high efficacy agonists that exert behavioral effects when occupying relatively few opioid receptors. Its pseudoirreversible binding is expected to make antagonism by MCAM more difficult to surmount and to provide longer antagonist action than the currently used opioid receptor antagonists. Aim 1 will characterize long-term antagonism of heroin self-administration by MCAM in a food/drug choice procedure. Aim 2 will examine the ability of MCAM to antagonize the positive reinforcing and respiratory depressant effects of fentanyl and ultra- potent analogs alone and in mixtures with heroin or cocaine. Aim 3 will characterize the pharmacokinetic profile of MCAM, heroin, fentanyl and its derivatives, and cocaine, alone and in mixtures. Using a highly translatable species, this project will examine a novel opioid receptor antagonist that has the potential to save lives by preventing and reversing the adverse, and often lethal, effects of opioids. The availability of another safe, effective, and long-acting treatment could be advantageous for many patients (e.g., problems with compliance would be reduced by an extended-release, pseudoirreversible antagonist) and in many treatment settings (e.g., rural areas where the opioid epidemic is worsening and regular contact with treatment providers is not practical).
摘要 阿片类药物过量导致的死亡人数继续上升;从2015年至2016年, 吸毒过量芬太尼衍生物价格低廉,易于合成,效力强,并销售给不知情的人。 滥用海洛因或其他毒品。此外,据报道芬太尼衍生物的作用更难被抑制。 与海洛因的逆转相比,纳洛酮的逆转。阿片类药物滥用的药物治疗包括: 阿片受体激动剂美沙酮和丁丙诺啡对许多患者有效, 有局限性,包括转移和滥用,它们可能产生严重的不良影响,包括 呼吸抑制和死亡。阿片受体拮抗剂纳洛酮和纳洛酮避免了滥用 责任和不良影响的美沙酮和丁丙诺啡;然而,短期的行动和 可克服性限制了它们的有效性。一种作用时间较长的药物, 逆转阿片类药物的作用的方式,而不是通过增加剂量的激动剂可以改善 通过在救援后提供难以克服的延长保护, 因为吸毒过量我们在猴子身上的初步研究表明,假不可逆的μ阿片受体选择性 拮抗剂methocinnamox(MCAM)减少海洛因,但不是可卡因自我管理,减少选择 瑞芬太尼在食物/药物选择过程中,通过以下方式逆转和保护呼吸抑制: 海洛因,一次注射有效期为一周或更长。拟议的研究建立在这些令人信服的 数据,并检查长期拮抗剂特性和MCAM与 通常滥用阿片类药物,包括强效芬太尼类似物。假设MCAM优于 纳洛酮和纳洛酮逆转和预防阿片受体激动剂的作用,特别是, 当占据相对较少的阿片受体时产生行为效应的高效激动剂。其 假不可逆结合预期使MCAM的拮抗作用更难以克服, 比目前使用的阿片受体拮抗剂具有更长的拮抗作用。目标1将描述长期 MCAM在食物/药物选择过程中对海洛因自我给药的拮抗作用。目标2将审查 MCAM拮抗芬太尼和超氧阴离子的正性增强和呼吸抑制作用的能力 单独的有效类似物以及与海洛因或可卡因的混合物。目标3将描述药代动力学特征 MCAM、海洛因、芬太尼及其衍生物和可卡因的单独和混合物。使用高度可翻译的 物种,该项目将研究一种新的阿片受体拮抗剂,有可能挽救生命, 预防和扭转阿片类药物的不良影响,往往是致命的。另一个保险箱的可用性, 有效且长效的治疗对于许多患者是有利的(例如,遵守方面的问题 将通过延长释放的假不可逆拮抗剂降低)和在许多治疗环境中(例如, 农村地区的类阿片流行病正在恶化,与治疗提供者的定期联系不切实际)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES P FRANCE其他文献

CHARLES P FRANCE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES P FRANCE', 18)}}的其他基金

Methocinnamox (MCAM): A novel opioid receptor antagonist
Methocinnamox (MCAM):一种新型阿片受体拮抗剂
  • 批准号:
    10844948
  • 财政年份:
    2023
  • 资助金额:
    $ 49.24万
  • 项目类别:
A novel opioid receptor antagonist for treating abuse and overdose
一种用于治疗滥用和过量的新型阿片受体拮抗剂
  • 批准号:
    9892987
  • 财政年份:
    2019
  • 资助金额:
    $ 49.24万
  • 项目类别:
A novel opioid receptor antagonist for treating abuse and overdose
一种用于治疗滥用和过量的新型阿片受体拮抗剂
  • 批准号:
    10353379
  • 财政年份:
    2019
  • 资助金额:
    $ 49.24万
  • 项目类别:
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
Methocinnamox (MCAM):一种新型 α-阿片受体拮抗剂,用于治疗阿片类药物使用障碍
  • 批准号:
    10477526
  • 财政年份:
    2019
  • 资助金额:
    $ 49.24万
  • 项目类别:
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
Methocinnamox (MCAM):一种新型 α-阿片受体拮抗剂,用于治疗阿片类药物使用障碍
  • 批准号:
    10763458
  • 财政年份:
    2019
  • 资助金额:
    $ 49.24万
  • 项目类别:
A novel opioid receptor antagonist for treating abuse and overdose
一种用于治疗滥用和过量的新型阿片受体拮抗剂
  • 批准号:
    10561706
  • 财政年份:
    2019
  • 资助金额:
    $ 49.24万
  • 项目类别:
Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab
5-HT2C 激动剂氯卡色林作为可卡因抗体潜在治疗方法的评估
  • 批准号:
    9008117
  • 财政年份:
    2013
  • 资助金额:
    $ 49.24万
  • 项目类别:
Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab
5-HT2C 激动剂氯卡色林作为可卡因抗体潜在治疗方法的评估
  • 批准号:
    8714994
  • 财政年份:
    2013
  • 资助金额:
    $ 49.24万
  • 项目类别:
Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab
5-HT2C 激动剂氯卡色林作为可卡因抗体潜在治疗方法的评估
  • 批准号:
    8652970
  • 财政年份:
    2013
  • 资助金额:
    $ 49.24万
  • 项目类别:
Training in Drug Abuse Research: Behavior and Neurobiology
药物滥用研究培训:行为和神经生物学
  • 批准号:
    8266367
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了